Mark Girgis, MD
Surgical Oncology · Los Angeles, CANPI 1588826382
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,820 of the $2,768 with a category attached, or 65.7%. Intuitive Surgical accounts for 86.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $1,048 and has fallen 76.0% since, to $252 in 2025.
Across 29 payments — averaging $95.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Jazz Pharmaceuticals Inc.$175
- Endogastric Solutions, Inc$125
- Acell, Inc.$87
Across 7 payments — averaging $34,303 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GE HealthCare$240K
What the payments were for
- Travel & lodging$94834%
- Food & beverage$1,82066%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 26 | $2,381 |
| Jazz Pharmaceuticals Inc. | 1 | $175 |
| Endogastric Solutions, Inc | 1 | $125 |
| Acell, Inc. | 1 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,939
- ESOPHYX$125
How this compares
$2,768 in reported general payments places this provider in the 55th percentile of 209 surgical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 13 | $293 |
| Pantoprazole Sodium | 17 | $153 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Los Angeles
- Ronald HurstLos Angeles$76K
- James EconomouLos Angeles$27K
- Cristina FerroneLos Angeles$25K
- Lee ZuckermanLos Angeles$19K
- Scott UmLos Angeles$16K
- Lawrence MenendezLos Angeles$13K
- Sujit KulkarniLos Angeles$11K
- Mediget TeshomeLos Angeles$9K
- Joshua EllenhornLos Angeles$9K
- Jason CohenLos Angeles$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.